16 hours Ago By Defense World Staff
Lifesci Capital upgraded shares of Mereo BioPharma Group ( NASDAQ:MREO – Free Report ) to a strong-buy rating in a research report sent to investors on Monday morning, Zacks.com reports. MREO has been the subject of a number of other research reports.
Jefferies Financial Group began coverage on Mereo BioPharma Group in a report on Friday, December 6th. They issued a “buy” rating and a $7.00 target price for the company.
Needham & Company LLC reissued a “buy” rating and issued a $7.00 target price on shares of Mereo BioPharma Group in a research report on Tuesday, November 12th. Finally, Cantor Fitzgerald raised shares of Mereo BioPharma Group to a “strong-buy” rating in a report on Sunday, December 8th.
Four investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, Mereo BioPharma Group currently has a consensus rating of “Buy” and a consensus target price of $7.83.
Get Our Latest Report on Mereo BioPharma Group Mereo BioPharma Group Trading Up 12.4 % Institutional Investors Weigh In On Mereo BioPharma Group A number of large investors have recently made changes to their positions in MREO. Frazier Life Sciences Management L.
P. boosted its holdings in shares of Mereo BioPharma Group by 15.8% in the third quarter.
Frazier Life Sciences Management L.P. now owns 5,097,779 shares of the company’s stock worth $20,952,000 after buying an additional 696,408 shares during the last quarter.
State Street Corp bought a new position in Mereo BioPharma Group in the third quarter worth approximately $195,000. Polar Asset Management Partners Inc. boosted its stake in shares of Mereo BioPharma Group by 36.
0% during the 3rd quarter. Polar Asset Management Partners Inc. now owns 198,300 shares of the company’s stock worth $815,000 after acquiring an additional 52,500 shares during the last quarter.
Janus Henderson Group PLC grew its position in shares of Mereo BioPharma Group by 56.7% during the 3rd quarter. Janus Henderson Group PLC now owns 12,345,866 shares of the company’s stock valued at $50,865,000 after acquiring an additional 4,464,984 shares during the period.
Finally, Fred Alger Management LLC increased its stake in shares of Mereo BioPharma Group by 108.1% in the 3rd quarter. Fred Alger Management LLC now owns 102,582 shares of the company’s stock worth $422,000 after purchasing an additional 53,278 shares in the last quarter.
62.83% of the stock is currently owned by institutional investors. About Mereo BioPharma Group ( Get Free Report ) Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.
It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. Further Reading Five stocks we like better than Mereo BioPharma Group How to Choose Top Rated Stocks Top 3 Reasons to Invest in This Bond ETF for Stability and Growth What is a Stock Market Index and How Do You Use Them? 2 Drone Stocks Surging from Increased Media Attention What Investors Need to Know About Upcoming IPOs Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge Receive News & Ratings for Mereo BioPharma Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mereo BioPharma Group and related companies with MarketBeat.com's FREE daily email newsletter .
.
